The Intentional Product Manager Podcast

There are a handful of genuinely useful frameworks - the five-part outcome-driven roadmap, the capital-allocation lens for engineering spend, and the compounding platform sequencing example - but they are surrounded by significant warmup padding, host self-insertion, and well-worn career advice (networking = sales, go slow to go fast). The insight-per-minute rate is moderate at best.

“if you can't tie your roadmap to a financial or a strategic ah metric you are not operating at the right altitude”

“if that message is shifted depending on the room then your roadmap is weak”

The 'ADD' metaphor for healthcare orgs chasing endless problems is a fresh framing, and the capital-allocation treatment of roadmaps is a solid reframe, but most of the episode recycles widely-circulated product management wisdom: talk about outcomes not features, networking is like sales, leadership is about systems not output. Nothing is contrarian or first-principles.

“I think a lot of health tech companies, they can easily generate a list of say 25 problems that need to be solved that can make them a ton of money and a ton of margin”

“strong leaders treat the roadmap space really like capital allocation”

Matt Moore is a credible senior practitioner who has shipped a real AI product (ambient scribe in an EMR), led multi-level PM teams, and navigated a resistant CEO - he is clearly not a career podcast guest. However, he operates at a VP-equivalent level rather than a C-suite founder at meaningful scale, and the episode does not surface credentials that distinguish him from many experienced health-tech PMs.

“I was leading a team of product Managers and engineers to create, um, an embedded, what's called ambient scribe into, into an EMR electronic medical records system”

“it also didn't hurt that we added several million in bookings that same year after launched it”

The ambient scribe story and the capital-allocation hypotheticals give some concrete texture, but dollar figures are vague ('several million,' 'tens of millions'), companies and hospitals are unnamed, and most supporting evidence is illustrative rather than real reported data. The episode relies heavily on hypothetical examples rather than named facts.

“if a company has $20 million of engineering capacity then the question becomes where does that capital earn the highest rate of return over the next 24 to 36 months”

“you take a $5 million initiative, right? And let's say it misses its adoption targets for like two quarters”

The host asks one decent follow-up ('How do you convince the CEO otherwise?') but otherwise the conversation is a string of affirmations and host self-stories that break the guest's momentum. There is no pushback, no challenged claim, and several questions that are simply restatements of what the guest just said. It reads closer to a PR-friendly promotional chat than a rigorous interview.

“I just wanted to Jump in and say that. The last one especially resonated with me”

“Can everyone please listen to the last thing Matt said and re listen because it's, it's really, really important”